Evidence map›Paper›PMID 41118116›Full record

ArticleGenes & genomics2025

Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy.

Eun Bin Lee, Hye Jin Yun, Su Hwan Park, Eun Hee Ko, Young Jun Jung, Rui Liu, Yun-Yong Park, Jong-Ho Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eun Bin LeeDepartment of Health Sciences, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea.
Hye Jin YunDepartment of Health Sciences, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea.
Su Hwan ParkDepartment of Health Sciences, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea.
Eun Hee KoDepartment of Health Sciences, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea.
Young Jun JungNational Institute of Ecology (NIE), Seocheon, 33657, Republic of Korea.
Rui LiuState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Yun-Yong ParkDepartment of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
Jong-Ho LeeDepartment of Health Sciences, The Graduate School of Dong-A University, Busan, 49315, Republic of Korea. Topljh19@dau.ac.kr.ORCID http://orcid.org/0000-0002-4220-4875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is a highly aggressive primary brain tumor associated with poor prognosis and enhanced aerobic glycolysis (the Warburg effect), which facilitates rapid tumor growth and increases malignancy. Phosphofructokinase 2 (PFK2), also referred to as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), is a critical regulator of glycolysis and has been linked to tumorigenesis; however, the specific contributions of its isoforms to GBM pathobiology remain insufficiently defined.

objectiveThis study aimed to clarify the isoform-specific function of PFKFB4 in GBM by evaluating its expression pattern, clinical significance, and impact on tumor glycolytic flux, proliferation, and malignancy, as well as to investigate the therapeutic potential of selectively targeting PFKFB4.

methodsWe examined the expression profiles of PFK2 isoforms in GBM using publicly accessible datasets. The clinical relevance was determined by conducting survival analysis using The Cancer Genome Atlas (TCGA) database. Protein expression patterns were identified with the Human Protein Atlas. PFKFB4 expression in GBM cell lines was validated using quantitative real-time PCR and immunoblotting. Functional roles of PFKFB4 were further assessed by employing the selective inhibitor 5-(n-(8-methoxy-4-quinolyl)amino)pentyl nitrate (5MPN). Effects of 5MPN on cell viability, proliferation, glucose uptake, lactate production, migration, invasion, and protein expression (c-Myc, cyclin D1, MMP-2, MMP-9) were evaluated using WST-8 assay, colony formation, 2-NBDG uptake, lactate assay, wound healing, transwell assays, and immunoblotting.

resultsWe found that PFK2 isoforms-notably PFKFB4-are markedly overexpressed in GBM tissues and cell lines, with elevated PFKFB4 expression associated with worse patient prognosis. Pharmacological inhibition of PFKFB4 using the selective small-molecule inhibitor 5MPN reduced the Warburg effect, cell proliferation, and colony formation in GBM cells, while having minimal effects on normal human astrocytes. Additionally, PFKFB4 inhibition diminished GBM cell migration and invasion, coinciding with a reduction in the expression of matrix metalloproteinases MMP-2 and MMP-9.

conclusionThese results underscore the oncogenic role of PFKFB4 in enhancing the Warburg effect and promoting malignant phenotypes in GBM, and support its potential as a therapeutic target for GBM treatment.

Indexed as

Brain NeoplasmsGlioblastomaPhosphofructokinase-2Cell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGlycolysisHumansPFKFB4 protein, humanPhosphofructokinase-2Cell motilityGlioblastomaPFKFB4The Warburg effectTumor proliferation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.